Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L02BG04
|
| gptkbp:CASNumber |
gptkb:105816-04-4
|
| gptkbp:hasInChIKey |
OBLPEUPLXAWFNA-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H11N5
|
| gptkbp:hasSMILES |
N#Cc1ccc(cc1)C(=N/n2cccn2)c3ccc(cc3)C#N
|
| gptkbp:hasUNII |
T6X3OCM3ZU
|
| https://www.w3.org/2000/01/rdf-schema#label |
105816-04-4
|
| gptkbp:IUPACName |
gptkb:4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketedAs |
gptkb:Femara
|
| gptkbp:molecularWeight |
285.31 g/mol
|
| gptkbp:name |
gptkb:Letrozole
|
| gptkbp:PubChem_CID |
3902
CHEMBL716 DB01006 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:Femara
|
| gptkbp:usedFor |
aromatase inhibitor
treatment of hormone receptor positive breast cancer |
| gptkbp:bfsParent |
gptkb:Starlix
|
| gptkbp:bfsLayer |
5
|